HRP20230276T1 - Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni - Google Patents
Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni Download PDFInfo
- Publication number
- HRP20230276T1 HRP20230276T1 HRP20230276TT HRP20230276T HRP20230276T1 HR P20230276 T1 HRP20230276 T1 HR P20230276T1 HR P20230276T T HRP20230276T T HR P20230276TT HR P20230276 T HRP20230276 T HR P20230276T HR P20230276 T1 HRP20230276 T1 HR P20230276T1
- Authority
- HR
- Croatia
- Prior art keywords
- bendamustine
- use according
- liquid preparation
- volume
- individual
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims 19
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims 14
- 229960002707 bendamustine Drugs 0.000 title claims 14
- 239000000203 mixture Substances 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 claims 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 12
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 235000021023 sodium intake Nutrition 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613173P | 2012-03-20 | 2012-03-20 | |
| US201261669889P | 2012-07-10 | 2012-07-10 | |
| US201261678715P | 2012-08-02 | 2012-08-02 | |
| EP19151152.6A EP3533447B1 (en) | 2012-03-20 | 2013-03-15 | Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230276T1 true HRP20230276T1 (hr) | 2023-04-28 |
Family
ID=49212373
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190693TT HRP20190693T1 (hr) | 2012-03-20 | 2013-03-15 | Tekući sastav za upotrebu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima su potrebne smanjene zapremnine za davanje |
| HRP20230276TT HRP20230276T1 (hr) | 2012-03-20 | 2013-03-15 | Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190693TT HRP20190693T1 (hr) | 2012-03-20 | 2013-03-15 | Tekući sastav za upotrebu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima su potrebne smanjene zapremnine za davanje |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9000021B2 (enExample) |
| EP (3) | EP3533447B1 (enExample) |
| JP (6) | JP6224064B2 (enExample) |
| CN (2) | CN107157988A (enExample) |
| CA (1) | CA2867343C (enExample) |
| DK (2) | DK2827863T3 (enExample) |
| ES (2) | ES2718902T3 (enExample) |
| FI (1) | FI3533447T3 (enExample) |
| HK (1) | HK1243346A1 (enExample) |
| HR (2) | HRP20190693T1 (enExample) |
| HU (2) | HUE062230T2 (enExample) |
| LT (1) | LT2827863T (enExample) |
| PL (2) | PL3533447T3 (enExample) |
| PT (2) | PT3533447T (enExample) |
| RS (2) | RS58744B1 (enExample) |
| SI (2) | SI3533447T1 (enExample) |
| WO (1) | WO2013142359A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3895694A1 (en) | 2010-01-28 | 2021-10-20 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| RS58744B1 (sr) * | 2012-03-20 | 2019-06-28 | Eagle Pharmaceuticals Inc | Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje |
| DK2827862T3 (da) | 2012-03-20 | 2024-02-12 | Eagle Pharmaceuticals Inc | Formuleringer af bendamustin |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| EP3836921B1 (en) | 2018-08-17 | 2025-10-08 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
| WO2021014957A1 (ja) * | 2019-07-22 | 2021-01-28 | 富士フイルム株式会社 | ベンダムスチン注射液製剤 |
| WO2021161876A1 (ja) * | 2020-02-10 | 2021-08-19 | 富士フイルム株式会社 | ベンダムスチン液剤 |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (enExample) | 1903-10-08 | 1905-03-16 | ||
| US4071620A (en) | 1977-01-10 | 1978-01-31 | American Home Products Corporation | Stabilization of oxygen sensitive dose forms |
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| US5223515A (en) | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
| BR9506564A (pt) | 1994-01-24 | 1997-09-02 | Procter & Gamble | Processo para solubilizar ativos farmacêuticos de dificil solubilidade |
| ES2373864T3 (es) | 1998-04-20 | 2012-02-09 | Eisai R&D Management Co., Ltd. | Composición estabilizada que contiene un compuesto de tipo bencimidazol. |
| WO2002032427A1 (en) | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| PT1553940E (pt) | 2002-07-30 | 2008-05-09 | Wyeth Corp | Formulações parentéricas contendo um hidroxi-éster de rapamicina |
| US20060035945A1 (en) | 2003-05-30 | 2006-02-16 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| US20060128777A1 (en) | 2004-11-05 | 2006-06-15 | Bendall Heather H | Cancer treatments |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2007026771A1 (ja) * | 2005-08-31 | 2007-03-08 | Ono Pharmaceutical Co., Ltd. | 点滴用注射剤 |
| CA2659562A1 (en) | 2006-08-14 | 2008-02-21 | Eisai R&D Management Co., Ltd. | Stable lyophilized preparation |
| WO2008044029A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| DE102007003184A1 (de) | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Verfahren zur Beladung von strukturierten Oberflächen |
| US20090082416A1 (en) | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched bendamustine |
| AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| JP5670335B2 (ja) | 2008-09-25 | 2015-02-18 | セファロン、インク． | ベンダムスチン液体製剤 |
| MX2011007557A (es) | 2009-01-15 | 2011-08-12 | Cephalon Inc | Formas nuevas de bendamustina como base libre. |
| RU2591804C2 (ru) | 2009-02-25 | 2016-07-20 | Супратек Фарма, Инк. | Композиции бендамустина и циклополисахарида |
| US20100273730A1 (en) | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| CN102413816A (zh) | 2009-04-28 | 2012-04-11 | 赛福伦公司 | 苯达莫司汀的口服制剂 |
| CN101584668A (zh) * | 2009-06-19 | 2009-11-25 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀冻干粉针剂 |
| WO2010148288A2 (en) | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| US8389558B2 (en) | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US20110015245A1 (en) | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| EP3895694A1 (en) | 2010-01-28 | 2021-10-20 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| US9655898B2 (en) | 2010-07-28 | 2017-05-23 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
| EP3712173B1 (en) | 2011-12-05 | 2023-07-12 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
| WO2013112762A1 (en) * | 2012-01-24 | 2013-08-01 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| JP2015506989A (ja) | 2012-02-14 | 2015-03-05 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチン製剤 |
| DK2827862T3 (da) | 2012-03-20 | 2024-02-12 | Eagle Pharmaceuticals Inc | Formuleringer af bendamustin |
| RS58744B1 (sr) | 2012-03-20 | 2019-06-28 | Eagle Pharmaceuticals Inc | Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje |
-
2013
- 2013-03-15 RS RS20190433A patent/RS58744B1/sr unknown
- 2013-03-15 CN CN201710292508.7A patent/CN107157988A/zh active Pending
- 2013-03-15 JP JP2015501814A patent/JP6224064B2/ja active Active
- 2013-03-15 PL PL19151152.6T patent/PL3533447T3/pl unknown
- 2013-03-15 PT PT191511526T patent/PT3533447T/pt unknown
- 2013-03-15 HR HRP20190693TT patent/HRP20190693T1/hr unknown
- 2013-03-15 LT LTEP13765020.6T patent/LT2827863T/lt unknown
- 2013-03-15 EP EP19151152.6A patent/EP3533447B1/en active Active
- 2013-03-15 CA CA2867343A patent/CA2867343C/en active Active
- 2013-03-15 RS RS20230252A patent/RS64137B1/sr unknown
- 2013-03-15 HU HUE19151152A patent/HUE062230T2/hu unknown
- 2013-03-15 US US13/838,267 patent/US9000021B2/en active Active
- 2013-03-15 PT PT13765020T patent/PT2827863T/pt unknown
- 2013-03-15 ES ES13765020T patent/ES2718902T3/es active Active
- 2013-03-15 WO PCT/US2013/032295 patent/WO2013142359A1/en not_active Ceased
- 2013-03-15 PL PL13765020T patent/PL2827863T3/pl unknown
- 2013-03-15 DK DK13765020.6T patent/DK2827863T3/en active
- 2013-03-15 SI SI201332039T patent/SI3533447T1/sl unknown
- 2013-03-15 CN CN201380023660.5A patent/CN104271135B/zh not_active Expired - Fee Related
- 2013-03-15 EP EP23161418.1A patent/EP4218756A1/en not_active Withdrawn
- 2013-03-15 HU HUE13765020 patent/HUE044233T2/hu unknown
- 2013-03-15 DK DK19151152.6T patent/DK3533447T3/da active
- 2013-03-15 EP EP13765020.6A patent/EP2827863B1/en active Active
- 2013-03-15 SI SI201331394T patent/SI2827863T1/sl unknown
- 2013-03-15 ES ES19151152T patent/ES2943668T3/es active Active
- 2013-03-15 HR HRP20230276TT patent/HRP20230276T1/hr unknown
-
2014
- 2014-11-26 US US14/554,269 patent/US20150080444A1/en not_active Abandoned
-
2015
- 2015-03-15 FI FIEP19151152.6T patent/FI3533447T3/fi active
- 2015-08-06 US US14/820,291 patent/US9579384B2/en active Active
-
2017
- 2017-10-04 JP JP2017193917A patent/JP6381761B2/ja active Active
-
2018
- 2018-02-28 HK HK18102930.9A patent/HK1243346A1/zh unknown
- 2018-07-31 JP JP2018143022A patent/JP6738376B2/ja active Active
-
2020
- 2020-05-29 JP JP2020093802A patent/JP2020143143A/ja active Pending
-
2021
- 2021-11-17 JP JP2021186829A patent/JP2022028813A/ja active Pending
-
2023
- 2023-12-15 JP JP2023212014A patent/JP2024037915A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230276T1 (hr) | Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni | |
| JP2015510940A5 (enExample) | ||
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| HRP20250266T1 (hr) | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c | |
| HRP20241087T1 (hr) | Konjugirani protusmisleni spojevi za upotrebu u terapiji | |
| HRP20160400T1 (hr) | Parenteralna primjena tapentadola | |
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| HRP20220978T1 (hr) | Upotreba oksidiranih kolesterol sulfata (ocs) za liječenje disfunkcije bubrega | |
| FI2827862T3 (fi) | Bendamustiinin formulaatioita | |
| JO3659B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية | |
| HRP20240034T1 (hr) | Liječenje kardiovaskularnih bolesti | |
| ME02520B (me) | Farmaceutske kompozicije | |
| JP2011511072A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2015510939A5 (enExample) | ||
| JP2016512564A5 (enExample) | ||
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| HRP20191248T1 (hr) | Kombinirana terapija za liječenje karcinoma jajnika | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| HRP20201632T1 (hr) | Režimi doziranja melflufena kod raka | |
| HRP20130150T1 (hr) | Sustav pakiranja farmaceutskih sastava i komplet za intravenozno davanje | |
| Schrey et al. | Antifungal drugs | |
| Sanchez-Torres et al. | 9073 Pemetrexed (PEM) safety and pharmacokinetics (PK) in patients (pts) with third-space fluid (TSF): final results of a phase II study | |
| Kotsakis et al. | 9075 Phase I study of the combination of docetaxel (D) and pemetrexed (P) in patients with advanced unresectable or metastatic non small cell lung cancer (NSCLC) | |
| Robl et al. | Chemotherapy revived-intraarterial cisplatin-based chemotherapy in an osteosarcoma xenograft model |